Answers are grounded in this paper and cite their sources.
ackground: Tamoxifen is the first line of treatment in hormone receptor-positive breast cancer. Letrozoleis developed for postmenopausal patients and metastatic breast cancer. Patients with concomitant chronictoxoplasmosis are at risk of reactivation of tissue cysts. It is still unknown whether these drugs will causeprotection against reactivated toxoplasmosis or exacerbated symptoms.Objective: This study aimed to investigate the possible effect of Tamoxifen and Letrozole on T. gondii freedbradyzoites in case of rupture tissue cyst with their subsequent reactivation to tachyzoites.Material and Methods: The study was conducted using in vitro cultured T. gondii tachyzoites in a culturedVero cell line. Different concentrations of Tamoxifen and Letrozole were used (0.24-125 ug/ml). Antiproliferativeeffect was determined by methyl thiazolyl tetrazolium (MTT) cytotoxicity assay estimated ascell line viability% reflecting the inhibition of tachyzoites proliferation after 24 and 48 h treatment. Antiinvasiveeffect was determined by counting Giemsa-stained intracellular tachyzoites inside infected Verocells using light microscopy. Induced cytotoxic morphological changes in the tachyzoites was determinedby transmission electron microscopy (TEM).Results: By MTT, cytotoxicity of both drugs to the infected cultured Vero cells indirectly assayed thedecreased tachyzoites proliferation compared to the control drug-free parasites (P<0.01). Letrozoleproved to be more cytotoxic than Tamoxifen after 48 h treatment (P<0.05). Both drugs decreased theability of tachyzoites' invasion compared to drug-free tachyzoites (P<0.05) with no statistical differencebetween the used drugs. Additionally, TEM demonstrated tachyzoites damage caused by both drugs.Conclusion: Tamoxifen and Letrozole demonstrated anti-toxoplasmic activity, indicating that administeringthese drugs in cancer patients may also prevent the possibility of reactivated toxoplasmosis. In vivo studiesare recommended to evaluate their efficacy.
No takes yet. Share an insight, caveat, or question.
Zahran et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: